Ascendis Pharma A/S (NASDAQ: ASND) is a Danish biopharmaceutical company developing long-acting prodrug therapies using its TransCon™ platform. Its approved product, Skytrofa, targets growth hormone deficiency, while its pipeline includes endocrinology and oncology assets. Ascendis is a high-profile biotech growth name with late-stage catalysts and commercial ramp-up underway.
最新股票文章

英伟达股票预测:第三方价格目标
自2025年年初以来,截至4月中旬,英伟达(NVDA)股价下跌约27.37%,但同比上涨26.48%。基于4月22日开盘价98.78美元,自1月初以来,英伟达股票波动显著,受到行业特定因素以及围绕美国贸易关税的更广泛股市不确定性影响。
17:42, 19 五月 2025


